61N1 Stock Overview
A vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
StageZero Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.018 |
| 52 Week High | CA$0.042 |
| 52 Week Low | CA$0.015 |
| Beta | 0.074 |
| 11 Month Change | 0% |
| 3 Month Change | -7.89% |
| 1 Year Change | -56.25% |
| 33 Year Change | -93.52% |
| 5 Year Change | -97.71% |
| Change since IPO | -98.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 61N1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | -56.3% | -16.9% | 9.1% |
Return vs Industry: 61N1 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 61N1 underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| 61N1 volatility | |
|---|---|
| 61N1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 61N1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 61N1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 40 | James Howard-Tripp | www.stagezerolifesciences.com |
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.
StageZero Life Sciences Ltd. Fundamentals Summary
| 61N1 fundamental statistics | |
|---|---|
| Market cap | €3.34m |
| Earnings (TTM) | -€11.56m |
| Revenue (TTM) | €2.76m |
1.2x
P/S Ratio-0.3x
P/E RatioIs 61N1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 61N1 income statement (TTM) | |
|---|---|
| Revenue | US$2.99m |
| Cost of Revenue | US$2.52m |
| Gross Profit | US$471.40k |
| Other Expenses | US$13.00m |
| Earnings | -US$12.53m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 15.75% |
| Net Profit Margin | -418.65% |
| Debt/Equity Ratio | -15.0% |
How did 61N1 perform over the long term?
See historical performance and comparison